Back
Staar Surgical 10K Form
Sell
38
STAA
Staar Surgical
Last Price:
$24.77
Seasonality Move:
3.5%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-07 | 10Q | STAA/Staar Surgical Quarterly |
2023-11-06 | 10Q | STAA/Staar Surgical Quarterly |
2023-08-02 | 10Q | STAA/Staar Surgical Quarterly |
2023-05-03 | 10Q | STAA/Staar Surgical Quarterly |
2022-11-02 | 10Q | STAA/Staar Surgical Quarterly |
2022-08-10 | 10Q | STAA/Staar Surgical Quarterly |
Receive STAA News And Ratings
See the #1 stock for the next 7 days that we like better than STAA
STAA Financial Statistics
Sales & Book Value
Annual Sales: | $322.4M |
---|---|
Cash Flow: | $-2.4M |
Price / Cash Flow: | 45.43 |
Annual Sales: | $8.69 |
Price / Book: | 2.78 |
Profitability
EPS (TTM): | 0.44000 |
---|---|
Net Income (TTM): | $21.8M |
Gross Margin: | $252.7M |
Return on Equity: | 5.46% |
Return on Assets: | 4.35% |
Staar Surgical Earnings Forecast
Key Staar Surgical Financial Ratios
-
The Gross Profit Margin over the past 36 years for STAA is 78.36%.
-
The Selling, General & Administrative Expenses for STAA have been equal to 55.88% of Gross Profit Margin.
-
The Research & Development expenses have been 13.77% of Revenue.
-
The Interest Expense is -5.14% of Operating Income.
-
The Net Earning history of STAA is 6.62% of Total Revenues.
-
Per Share Earnings over the last 36 years have been positive in 18 years.
Staar Surgical Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Health Care Equipment & Supplies |
Sector: | Health Care |
Current Symbol: | STAA |
CUSIP: | 852312 |
Website: | staar.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 5.99 |
Quick Ratio: | 5.18 |
Price-to-Earnings
Trailing P/E Ratio: | 56.21 |
---|---|
Forward P/E Ratio: | 29.61 |
STAA Technical Analysis vs Fundamental Analysis
Sell
38
Staar Surgical (STAA)
is a Sell
Is Staar Surgical a Buy or a Sell?
-
Staar Surgical stock is rated a SellThe current Staar Surgical [STAA] share price is $24.17. The Score for STAA is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.